The U.S. Food and Drug Administration (FDA) has denied the New Drug Application (NDA) for Cladribine Tablets, EMD Serono’s proprietary investigational oral medication to treat the relapsing-remitting form of multiple sclerosis (MS).

“The company will work closely with the FDA to fully understand FDA’s concerns and define a path forward for a successful resubmission of this application at the earliest point in time,” Elmar Schnee, Member of the Executive Board Merck KGaA and Head of Pharmaceuticals said in a recent press release. “We remain focused on delivering on our promise to transform the way people living with multiple sclerosis approach their therapy options.” (more)

Can Do Multiple Sclerosis is the new name of the nation’s leading provider of lifestyle empowerment programs for people with multiple sclerosis (MS) and their support partners, announced Kim Sharkey, CEO, Can Do MS.

Formerly The Heuga Center for Multiple Sclerosis, Can Do MS conducted months of research, assessments, planning and strategic development to position its distinct competitive advantages in the fast-evolving field of MS care management. (more)

Source: University of Buffalo, www.buffalo.edu

Magnetic resonance images (MRI) of patients diagnosed with multiple sclerosis in childhood show that pediatric onset multiple sclerosis is more aggressive, and causes more brain lesions, than MS diagnosed in adulthood, researchers at the University at Buffalo have reported.

Interestingly, however, patients with pediatric-onset MS — which comprise up to 5 percent of total MS cases — develop disabilities at a slower pace than patients with adult-onset MS, the data showed. (more)